<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In an open pilot study, the authors tested whether the nonpeptide <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP) IIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="9605">tirofiban</z:chebi>, a highly effective and selective blocker of platelet aggregation, prevents the transition of ischemic brain tissue into the <z:mpath ids='MPATH_124'>infarct</z:mpath> proper as defined by MRI (perfusion-weighted/T2-weighted) in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (T2 lesion after 1 week) was smaller in treated patients (n = 10) compared with matched control subjects (n = 10; p = 0.029) with similar initial perfusion deficit (<z:chebi fb="1" ids="18284">TTP</z:chebi>-maps) </plain></SENT>
<SENT sid="2" pm="."><plain>The authors conclude that GP IIb/IIIa <z:chebi fb="68" ids="48706">antagonists</z:chebi> have therapeutic potential in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy </plain></SENT>
</text></document>